Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,501–14,600 of 15,747
A Rabies Virus Nucleocapsid-like Nanostructure Vaccine Based on Dual-Cationic Lipid Nanoparticles
Zhang, Z., Zhang, J., Mu, C., Ma, K., Gao, D., Liu, C., Lin, F., Peng, X., Si, J., Li, H., et al. (2025) · Vaccines · doi:10.3390/vaccines13121196
“These reactogenicities are largely attributed to innate immune activation induced by both the LNPs and the intrinsic immunostimulatory properties of mRNA [38–40].”
An Introduction to mRNA Vaccines in Cancer Nanomedicine
Ramadurai, K. W., & Banerjee, A. (2026) · SpringerBriefs in bioengineering · doi:10.1007/978-3-032-04012-1_1
İŞLER, Y., Kaya, H., Ortabük, A. F., Yüksel, M., & Ay, M. O. (2026) · Vaccines · doi:10.3390/vaccines14100841
Davies, M., van Hougenhouck-Tulleken, W. G., Diana, N. E., Chothia, M., Nel, J. S., Wearne, N., Wadee, S., & Hariparshad, S. (2021) · African Journal of Nephrology · doi:10.21804/24-1-4731
The effect of COVID-19 on cancer immunotherapy and cancer care
Niederhuber, J. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00022-8
De Novo Drug Design of Potential Inhibitors of the Receptor-Binding Domain of SARS-CoV-2 Variants
Lopez, E. C. R. (2023) · International Electronic Conference on Biomedicines (IECBM) · doi:10.3390/ecb2023-14371
“Several vaccines, such as those developed by Pfizer/BioNTech [2] and Moderna [3], among others, have already been deployed after showing promising efficacy rates in their clinical trials.”
BackgroundWatanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Takagi, T., & Fukuzawa, K. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14135138
Role of the NSR-ASCO ribonucleoprotein complex in the regulation of plant development
Rigo, R. (2021) · theses.fr (ABES) · doi:10.70675/c2844cd4z4c3az4a6azb70czbaf852dc8504 · Cited by 1
Nanomedicines and nanovaccines manufacturing
Mahaling, B., Baruah, N., Manthripragada, P., & Dinabandhu, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44579-8.00023-0
Adekola, J., Audu, J., Okey-Adibe, T., Abubakar, A., Lance, M., Blaize, C., & Miragoli, M. (2025) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-024-02277-6
“Second, it reduces the burden on the national healthcare systems, including the UK’s National Health Services (NHS), associated with COVID-19 hospitalisations and deaths [4].”
Sarı, O., & Tekin, K. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.21
You, J., Wu, H., Tian, J., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02509-5
“This demographic profile, comprising primarily younger patients, lower body mass index, fewer comorbidities, and a majority being vaccinated, deviated considerably from the typical demo-graphics seen in clinical trials of COVID-19 vaccines [18–20].”
BackgroundMarkovic, U., Scalisi, E., Giunta, G., Nardo, A., Duminuco, A., Parrinello, N. L., Marino, S., Iachelli, V., Milone, G. A., Scire, P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134648
“Therefore, oncological and hematological patients with active disease were included in the vulnerable group in Italy, even though a diagnosis of active malignancy represented an exclusion criterion in the pivotal trials [1,2].”
InfluentialKakeya, H., Kusunoki, H., Watanabe, Y., & Sakai, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10142117/v1
Liu, Y., Zhou, J., Gong, Z., Feng, Y., Li, X., Shang, Q., Wu, Y., & Yang, Y. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101612 · Cited by 2
COVID-19 vaccine-associated autoimmune thyroid eye disease: Graves’ orbitopathy
Murugan, A. K., Afnan, R., & Alzahrani, A. S. (2026) · Endocrine · doi:10.1007/s12020-026-04795-1
“As of 2026, 13.6 billion doses have been administered globally, and the triumph of this approach is evidenced by the high efficacy of the vaccines, such as the BNT162b2 mRNA vaccine that demonstrated 95% effi - cacy [7].”
InfluentialCOVID-19 and patients on renal replacement therapy: Perspective from the State of Qatar
Hamad, A., Alkadi, M. M., & Al-Malki, H. A. (2024) · Qatar medical journal · doi:10.5339/qmj.2024.1
“11,12 However, dialysis patients were excluded from earlier studies for safety considerations.”
BackgroundİNFERTİL HASTALARIN COVID-19 AŞISINA UYUMU VE IVF TEDAVİ SONUÇLARI
Mutlu, A. E., & Kaya, D. (2022) · Sağlık Bilimleri Dergisi · doi:10.34108/eujhs.1121522
A modeling framework for the analysis of the SARS‐CoV2 transmission dynamics
Chatzilena, A., Demiris, N., & Kalogeropoulos, K. (2024) · Statistics in Medicine · doi:10.1002/sim.10195
Jahromi, A. H., & Stoehr, J. R. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.101994
Design and Immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion proteinPreprint
Dormeshkin, D., Katsin, M., Stegantseva, M. V., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.06.511104
Older subjects and immunogenicity of mRNA COVID-19 vaccines
Seiffert, P., & Religa, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95648-2.00051-4
Zhou, J., Li, T., Zhang, W., Qiao, P., Zhang, H., Ding, Z., Lu, Y., Yu, J., Ding, J., Chen, H., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c04529 · Cited by 1
COVID-19 Vaccination Strategy and Evidence in Korea
Hwang, Y. H., & Park, W. B. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e114
Drug/gene delivery and theranostics
Wang, W., Shen, S., Guo, W., & Rao, L. (2023) · APL Bioengineering · doi:10.1063/5.0165227
Vaccine efficacy—the biggest challenge today
Lundstrom, K. H. (2026) · Exploration of Immunology · doi:10.37349/ei.2026.1003260
Ghosh, A., Kanta, P., Ramola, M., Mohindra, R., Goyal, K., Kishore, R., Suri, V., Lakshmi, P. V. M., Chauhan, C., Sharma, M. L., et al. (2024) · Current Microbiology · doi:10.1007/s00284-023-03603-7
“However, for most vaccines, efficacy in reducing asymptomatic infections is lower as compared to severe symptomatic infections [5, 6].”
ÇAK, E., & ÇELİK, Ş. (2023) · Bütünleyici ve Anadolu Tıbbı Dergisi · doi:10.53445/batd.1353861
Biomedical Research and Program Evaluation
Greenwald, H. P. (2022) · Wiley eBooks · doi:10.1002/9781119812234.ch8
Infectiologie : vaccins contre la COVID-19
Aupiais, C. (2021) · Perfectionnement en Pédiatrie · doi:10.1016/s2588-932x(21)00197-2
Imai, K., Kitagawa, Y., Tabata, S., Matsuoka, M., Nagura‐Ikeda, M., Fukada, A., Miyoshi, K., Saito, Y., Tarumoto, N., & Maeda, T. (2021) · Research Square · doi:10.21203/rs.3.rs-560458/v1
(2024) · doi:10.1101/2024.04.05.24305357
“35 For some level of response (“detectable” after dose 2), a slight separation was observed between “detectable” and healthy controls when displaying all 444 immune parameters; a stronger separation when only the 10 most highly associated immune parameters were displayed ( Figure 3A ).”
BackgroundMethodBarnay, M., Foubert‐Samier, A., Violleau, M., Salort‐Campana, E., Cintas, P., Laforêt, P., Mathis, S., Péréon, Y., Tard, C., Sirma, F., et al. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.04.007
Lv, X., Ji, L., Cao, W., Xue, Y., Dai, H., & Zhang, S. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1657691
Wienands, J. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211022109
Yang, Y., Song, T., Huang, K., Huang, H., Zhao, M., & Li, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091094
“…lipids that have reached clinical application include DLin-MC3-DMA (used in Onpattro), SM-102 (used in the Moderna COVID-19 vaccine), and ALC-0315 (used in the Pfizer–BioNTech COVID-19 vaccine), each with distinct performance profiles in terms of potency, tolerability, and biodistribution [25,26].”
Taito, K., Oka, M., Sugimoto, H., Fukagawa, H., Izawa, A., Tsuchiya, T., Matsuno, S., Yamanaka, N., Yumura, W., Suzuki, N., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02740-6
Modeling the role of latent period and vaccination in COVID-19 dynamics
Borah, P. B., Dehingia, K., Hınçal, E., Padder, A., & Sarmah, H. K. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00777-5 · Cited by 3
Estrella-Santiago, D. P., Pérez, F. S., & Espinoza, R. O. (2024) · Ciencia Docencia y Tecnología · doi:10.33255/3572/1987
Highlights from Stanford Drug Discovery Symposium 2021
Chase, A. J., Malhotra, S. V., Mercola, M. A., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab250
La vaccination contre la COVID-19 : pourquoi allonger l’intervalle entre les doses?
Quach, C., & Deeks, S. L. (2021) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2021-0323.fr
Arévalo, S. J. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-26102022-112347
Nikam, D. S., Dahivelkar, S. D., & Mali, S. B. (2024) · Journal of Academy of Dental Education · doi:10.25259/jade_23_2023
American COVID: An Econometric Analysis of Variants
McIntosh, J. (2024) · Global Journal of Health Science · doi:10.5539/gjhs.v16n12p43
“Clinical trials carried out in the latter half of 2020 on respondents exposed to the Wild-type variant showed efficacy rates for both Moderna and Pfizer-BioNTech at around 95%, Pfizer (2012), Baden, El Sahly & Essink et al (2022) and Polack et al. (2020).”
Stillwell, R. C. (2026) · Research Square · doi:10.21203/rs.3.rs-9962383/v1
Conlon, C. P., & Firth, J. D. (2020) · doi:10.1093/med/9780198746690.003.0650_update_002
Lambo, J., Keli, S., Kaplan, S. K., Njideaka-Kevin, T., Arja, S. B., Altahir, A. K. O., Olonade, I., & Kumar, R. (2024) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2024.2399108
“The Pfizer BioNTech BNT162b2 and Moderna mRNA-1273 vaccines have demonstrated durable clinical responses with short-term, mild-to-moderate AEs [11–15].”
Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
Baeten, P., Beets, K., Schalley, T., Verreycken, J., Duran, G., Lintsen, D., Schuetz, L. T., Zhong, X. X., Nieuwschepen, R., Schepers, M., et al. (2026) · Advanced Science · doi:10.1002/advs.76382 · Cited by 2
“…studies (e.g., NCT04602390; NCT04602390; NCT05660109) across multiple autoimmune diseases [ 5–10 ]. mRNA-based technologies have transformed immunotherapy, as demonstrated by their success in infectious disease vaccines and cancer, where they have been exploited primarily to elicit immunity [ 11 ].”
The revolution of personalized medicine is already upon us in rare diseases
Austin, C. P. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0009
Zhao, Z., Wang, B., Wang, H., Zhang, Q., Liang, Y., & Liu, Y. (2026) · Vaccines · doi:10.3390/vaccines14050397
“The success of LNP-containing mRNA vaccines, such as Comirnaty and Spikevax, during the COVID-19 pandemic has underscored the immense potential of LNP technology [27,28].”
Lakhanpal, V., Sharma, B., Upadhayay, P., & Kant, K. (2024) · Tropical Doctor · doi:10.1177/00494755241308003
Öztürk, R. (2022) · Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi · doi:10.20492/aeahtd.940534
Sun, S., Yang, C., Wen, Y., Zu, H., Lu, H., Cheng, X., Han, J., Ma, H., Zhang, Y., Jiang, Y., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09907
Almeida, N. M. G., Ferreira, M. I. P. L., & Félix, M. M. R. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200053
Clearly Defining Re-exposure Protection And Vaccine Efficacy Statistical ResultsPreprint
Epperly, D. E. (2021) · doi:10.31219/osf.io/fn46p
Nair, A., & Kis, Z. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.109034
Κοντοπούλου, Κ., Nakas, C. T., Tsekoura, M., Tsorbatzoglou, M., & Papazisis, G. (2026) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2026.02784
Machin, D., Fayers, P. M., & Tai, B. C. (2021) · Wiley eBooks · doi:10.1002/9781119524687.refs
Nanoscale Vaccines for the Prevention of COVID-19
Iqbal, M. J., Hamdani, T., Attarwala, H. Z., & Amiji, M. M. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_13
Jannat, T., Sarker, M. M. R., Alam, S., et al. (2023) · Healthmed Journal of Pharmaceutical Sciences · doi:10.64461/hjps.v01i01y23.02
Savaşçı, Ü., Ayaz, T., UYSAL, B., & Doğan, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4118569
Yechezkel, M., Qian, G. L., Levi, Y., Davidovitch, N., Shmueli, E., Yamin, D., & Brandeau, M. L. (2023) · medRxiv · doi:10.1101/2023.06.28.23292007
Han, X., Wang, W., & Wang, Y. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179648
Modifying SARS-CoV-2 vaccine schedule in Spain: When numbers matters
Díaz‐Menéndez, M., & Malmierca, E. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2021.01.005
Тарасова, А. А., Костинов, М. П., & Kvasova, M. A. (2022) · Infectious diseases News Opinions Training · doi:10.33029/2305-3496-2022-11-4-118-126
Bhattacharya, D., Kanungo, S., Palo, S. K., Kshatri, J. S., Pattnaik, M., Ghosal, S., Mohapatra, P., Rao, C. M., Sahoo, A., Mishra, R. P., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1041586
Takano, T., Hirose, M., Yamasaki, Y., Hara, M., Okada, T., & Kunishima, H. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3921161
Najih, M., Boussettine, R., Kehel, M. E., Ansari, F. Z. E., Tadlaoui, K. A., & Ennaji, M. M. (2024) · World Academy of Sciences Journal · doi:10.3892/wasj.2024.294
Population Impact of SARS-CoV-2 Variants with Enhanced Transmissibility and/or Partial Immune EscapePreprint
Bushman, M., Kahn, R. J., Taylor, B. P., Lipsitch, M., & Hanage, W. P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3924614
Cherne, M. D., Snyder, D. T., Sidar, B., Blackwell, K., Jenkins, B. R., Huang, S., Sebrell, T. A., Hedges, J. F., Spence, J. R., Chang, C. B., et al. (2025) · medRxiv · doi:10.1101/2025.03.24.25324570 · Cited by 1
Adverse Events of COVID-19 Vaccine in Japanese University Students
Otaka, Y., TAJIMA, K., Kimura, Y., Itoh, N., Kanai, K., & Ueno, S. (2023) · Journal of Veterinary Epidemiology · doi:10.2743/jve.27.39
Zimmer, D. N., Schmid, F., & Settanni, G. (2026) · Small · doi:10.1002/smll.202513399 · Cited by 3
Burns, J., Rivers, P. S., LeClair, L. B., Jovel, K. S., Rai, R. P., Lowe, A. A., Edwards, L., Khan, S. R., Mathenge, C., Ferraris, M., et al. (2022) · doi:10.2196/preprints.37929
Kizek, Ö., Yalçın, G. Y., Gündüz, T., Kürtüncü, M., & Eraksoy, M. (2022) · Turkish Journal Of Neurology · doi:10.4274/tnd.2022.97493
The RNA-based immunotherapy and future perspectives
Atalay, B. R., Aydemir, E., & Ayaz, F. (2025) · Discover Immunity. · doi:10.1007/s44368-025-00012-9
Mumena, D. K., Kwenda, G., Ngugi, C. W., & Nyerere, A. K. (2022) · IP International Journal of Medical Microbiology and Tropical Diseases · doi:10.18231/j.ijmmtd.2022.040 · Cited by 2
Insights into Molecular Mechanisms Underlying COVID-19 Pathogenesis and Potential Therapeutics
Ravula, S., Mullaguri, S. C., Akula, S., Silveri, R., & Kancha, R. K. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.839
Waki, K., Tani, H., Kawahara, E., Saga, Y., Shimada, T., Yamazaki, E., Koike, S., Morinaga, Y., Isobe, M., & Kurosawa, N. (2025) · eLife · doi:10.7554/elife.88387.2
Characteristic Features of SARS CoV-2
Bakhat, S., & Taj, Y. (2021) · Journal of Bahria University Medical and Dental College · doi:10.51985/fnwg4302
Zhang, J. (2023) · Springer series in biophysics · doi:10.1007/978-3-031-36773-1_27
Muller, W. J., Jhaveri, R. R., Heald-Sargent, T. A., Macy, M. L., Heard‐Garris, N., Shah, S. K., & Paquette, E. (2023) · Clinical Trials · doi:10.1177/17407745231217299 · Cited by 1
The microRNA miR-132 is a key regulator of lymphatic vascular remodellingPreprint
Arcucci, V., Ishaq, M., Roufail, S., Dredge, B. K., Bert, A. G., Hackett-Jones, E., Liu, R., Pillman, K. A., Fox, S. B., Stacker, S. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473780
Desenvolvimento e importância das vacinas: por que ainda é preciso afirmar o óbvio?
Filho, M. D. V. C. S. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n4-187
Cell‑intrinsic mechanisms underlying species differences in lipid nanoparticle‑mRNA deliveryPreprint
Goihberg, P., Martyniak, K., Hickey, J., Jami‐Alahmadi, Y., Soo, P. L., Narula, J., & Neubert, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9180848/v1
Emergency surgical tracheotomy in the era of COVID-19 pandemic
Muriana, P., Ciriaco, P. P., Carretta, A., & Negri, G. (2021) · Signa Vitae · doi:10.22514/sv.2021.055
The Importance of English in Technical and Scientific Education
Simas, L. (2026) · Creative Education · doi:10.4236/ce.2026.174042 · Cited by 1
Frailty in Critically Ill Patients with COVID-19: The Lessons Learned
Subramaniam, A., Ling, R. R., & Shekar, K. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_4
[Adverse effect incidence of Pfizer/BioNTech COVID-19 vaccine: Retrospective cohort study].
Martínez-Roa, A. C., Labra-Rubio, L., & Landeros-Navarro, I. Y. (2023) · PubMed Central
Subramani, C., & Barman, T. K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102659
Wettengel, J. M., Strehle, K., von Lucke, C., et al. (2022) · medRxiv · doi:10.1101/2022.12.08.22283259
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.